Phase 2 N=17 An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Prostatitis · Chronic Prostatitis With Chronic Pelvic Pain Syndrome
Primary: Global Response Assessment — 2 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=440 Acupuncture for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Chronic Prostatitis With Chronic Pelvic Pain Syndrome
Primary: Proportion of Responders at the End of 8-week — 60.6; 36.8 percentage of participants
Phase 3 N=242 An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis
Prostatitis
Primary: Clinical Success — 46; 48; 52 Participants
Phase 2 N=62 An Efficacy And Safety Study Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis
Chronic Prostatitis With Chronic Pelvic Pain Syndrome
Primary: Change From Baseline in Average Daily Pain Score at Week 6 — 5.5; 5.6; -1.4; -1.0 units on a scale
Phase 2 N=151 Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.
Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Primary: National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) Total Score. — 26.0; 26.8; 27.9; -12.1 Units on a 0 to 43 scale
Phase 3 N=324 Efficacy & Safety Study of Pregabalin to Treat Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)
Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)
Primary: Decrease in the NIH-CPSI Total Score by at Least 6 Points — 103; 38 Participants
Phase 3 N=272 Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Prostatitis
Primary: Number of Participants With Decline in Total Score ≥4 for the NIH-CPSI Total Score From Baseline to 12 Weeks — 68; 66 Participants — p=0.99
Phase 3 N=139 Efficacy Study of a Standardized Pollen Extract Preparation (Cernilton) to Treat Inflammatory Chronic Prostatitis-Chronic Pelvic Pain Syndrome (CP-CPPS)
Chronic Prostatitis · Chronic Pelvic Pain Syndrome
Primary: Symptomatic Improvement in the Pain Domain of National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) — 47; 33 participants — p=<0.05
Phase 4 N=510 Antibiotic Prophylaxis for Transrectal Prostate Biopsy
Infection
Primary: Number of Participants With Post-biopsy Infection. — 6; 3 participants — p=<0.05
Phase 2 N=92 Transperineal Intraprostatic Injection of PRX302 Under Ultrasound Guidance for Management of Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Primary: Change in International Prostate Symptom Scale (IPSS) of Lower Urinary Tract Symptoms From Baseline to 3 Months (Total Score at 3 Months Minus Total Score at Baseline)…
N/A N=687 PReclude Infection EVEnts With No Prophylaxis Transperineal Biopsy
Infection
Primary: Percentage of Subjects That Experienced Infection, Urinary Retention or Bleeding Requiring Intervention Within 7 Days of Biopsy Based on Transrectal Ultrasound Guided…
Phase 3 N=420 Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Benign Prostatic Hypertrophy
Primary: International Prostate Symptom Score (IPSS) — -6.2; -5.1; -5.7 Units on a scale — p=0.371
N/A N=9 Prostate Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Prostatic Hyperplasia, Benign · Enlarged Prostate With Lower Urinary Tract Symptoms
Primary: Number of Participants With Adverse Events — 3 Participants
N/A N=21 Prostate Artery Embolization (PAE) for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Benign Prostatic Hyperplasia
Primary: Number of Adverse Events Reported — 7 adverse events
Phase 3 N=528 Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)
Benign Prostatic Hypertrophy
Primary: IPSS Change From Baseline — -5.6 Units on a scale — p=<0.001
N/A N=139 Evaluating the Effect of the Probiotic on Recurrent Urinary Tract Infection in Adult Women
Recurrent Urinary Tract Infection in Adult Women
Primary: To Evaluate the Effect of Oral Supplementation With Lactobacillus Reuteri on the Frequency of Confirmed UTI in Adult Women With Recurrent UTI. — 1.2; 1.3 Number of…
Phase 2 N=100 An Efficacy Trial of Electroacupuncture at Points of Bilateral BL33 for Mild and Moderate Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia (BPH)
Primary: Change of IPSS at the 6th Week Compared With Baseline(Intention to Treat) — 7.26; 2.34 units on a scale — p=< 0.01
Phase 2 N=15 Prostate Embolization for Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Primary: Number of Participants With Bladder or Rectal Injury — 0 Participants
Phase 2 N=134 Botulinum Toxin Injection for the Management of BPH
Benign Prostatic Hyperplasia
Primary: Improvement in the AUA Symptom Score Index by 30% From Baseline Within the First 12 Weeks After Injection. — 46; 50 participants — p=<0.05
N/A N=197 Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
Benign Prostatic Hyperplasia · Lower Urinary Tract Symptom
Primary: Efficacy: Change From Baseline in the International Prostate Symptom Score (IPSS) at 3 Month Follow-Up — -11.2; -4.3 Cange in IPSS score
Phase 2 N=315 Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Primary: Change From Baseline in the Total International Prostate Symptom Score (IPSS) at Week 12 — 21.8; 21.5; -6.3; -5.6 Score on a scale
N/A N=45 Prostatic Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia (BPH)
Benign Prostatic Hyperplasia (BPH)
Primary: The Primary Objective is to Evaluate the Safety of Prostate Artery Embolization (PAE) for the Treatment of Lower Urinary Tract Symptoms (LUTS) Attributed to Benign…
N/A N=28 Prostatic Artery Embolization (PAE) for Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) Using Bead Block Microspheres
Benign Prostatic Hyperplasia (BPH)
Primary: Number of Reported Treatment-related Adverse Events (AE) as Assessed by NCI CTCAE Grading Scale . — 6; 10; 0; 0 events — p=0.05
Phase 4 N=395 Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1
Bladder Outlet Obstruction
Primary: The Global Response Assessment (GRA) After the Treatment Day — 89; 218; 27; 61 participants
Phase 2 N=75 Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
Prostate Adenocarcinoma · Prostate Cancer · High Risk Prostate Cancer
Primary: Percentage of Participants With Pathologic Complete Response (pCR) or Minimal Residual Disease (MRD) — 30; 16 percentage of participants — p=0.151
Phase 3 N=511 A Study of Tadalafil in Men With Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia (BPH)
Primary: Change From Baseline in Total International Prostate Symptom Score (IPSS) at 12 Weeks — -4.2; -6.3; -5.7 units on a scale — p=0.001
N/A N=50 Rezum I Pilot Study for Benign Prostatic Hyperplasia
Prostatic Hyperplasia · Benign Prostatic Hyperplasia · Adenoma, Prostatic
Primary: International Prostate Symptom Score (IPSS) Change From Baseline — -0.4; -5.0; -13.1; -12.6 score on a scale
Phase 3 N=97 A Study in Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Primary: Change From Baseline to 8-Week Endpoint in Arterial Resistive Index (RI) in the Prostate Transition Zone — -0.01; 0.00 ratio — p=0.121
Phase 3 N=325 Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily
Benign Prostatic Hyperplasia
Primary: Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS) — -5.6; -3.6 Units on a Scale — p=0.004
Phase 3 N=1,070 A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
Benign Prostatic Hyperplasia · Enlarged Prostate
Primary: Change in Total International Prostate Symptom Score (IPSS) From Baseline to 12 Weeks — -5.18; -3.76 units on a scale — p=0.001